Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | PTGES | O14684 | 2/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.53 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120145 | 0.94 | KMT2A (1.00) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL2119498 | 0.91 | KMT2A (1.00) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL2119250 | 0.88 | MEN1 (1.00) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL2119875 | 0.84 | KMT2A (1.00) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL2122421 | 0.82 | MEN1 (1.00) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL1711098 | 0.80 | MEN1 (0.76) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL11712969 | 0.80 | KMT2A (0.71) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL2121576 | 0.80 | KMT2A (1.00) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL2117091 | 0.79 | KMT2A (1.00) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL3278663 | 0.75 | PTGES (0.84) | KMT2AMEN1ALDH1A1LMNAPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | KMT2A 941/4885MEN1 1593/4885POLB 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.